Sidra Medicine discovers new mutation that affects Covid-19 testing

  • 7 months   ago
A study has been discovered and published on a novel point mutation in the SARS-Cov-2 genome that results in affecting the Covid-19 testing by an FDA approved test. This study was jointly led by the teams from Pathology and the Genomics Core at Sidra Medicine.
This study has revealed that the testing centers across the globe must monitor mutations in the infectious diseases and must make sure that all the testing methods are up-to-date, and based on numerous gene targets to avoid detecting possible false-negative results.
The research findings that were published in the Journal of Clinical Microbiology, makes note of Sidra Medicine’s constant and vital part in supporting global efforts to tackle the disruptive epidemic and finds efficient, robust and preventive testing method for Covid-19.
Dr. Mohammad Rubayet Hasan, Clinical Molecular Microbiologist from the Pathology Department at Sidra Medicine, who led the study, stated: “Since the beginning of the pandemic, worldwide labouratory testing to detect Covid-19 by real-time reverse transcription PCR (RT-qPCR) has played a central role in mitigating the spread of the virus. Soon after the viral genome sequences were available, several RT-qPCR assays were developed and made available by the World Health Organization for public use. However, the large-scale sustained person-to-person transmission of Covid-19 has led to many mutational events, some of which may affect the sensitivity and specificity of available PCR assays (tests).
 In order to diagnose Covid-19, most laboratories test for multiple gene targets. The Sidra Medicine team received samples from several unrelated patients who were positive for only one viral gene target, which led them to suspect that some of the viruses circulating in the country may have this common mutation. By examining such a genetic sequence of these viruses, they identified a new mutation in a commonly used gene target for Covid-19 detection and discovered that the same mutation was present in viruses recovered from epidemiologically unrelated individuals. They also analysed that this particular mutation had not been reported by any other country.
Dr Hasan further said that, “Current testing methods have played a central role in mitigating the virus's spread through early detection, tracing suspected cases, and screening at-risk populations. Therefore the implications of inaccurate test results could cause health authorities to lose track of Covid-19 positive individuals. Infected patients may unknowingly spread the virus, and the erroneous test results could affect infected individuals' medical care. Our study concludes that it is essential to ensure RT-qPCR methods used for Covid-19 testing are up to date and inclusive of such variants in case further mutations make the virus undetectable by existing molecular tests.”
The specific mutation made known in the study originated at a viral gene utilized by a WHO-recommended assay, which is developed by the Centers for Disease Control and Prevention (CDC) in the United States.
Dr. Patrick Tang, Division Chief of Microbiology at Sidra Medicine said: “This study is testament to the excellence of our pathology and research expertise at Sidra Medicine. We remain committed to tackling this pandemic. Our efforts are backed by ongoing innovation and a drive to continually enhance current methods. I am very proud our ground-breaking findings and research that will help the population in Qatar as well as the global community.”
Our findings also highlighted the importance of testing for multiple SARS-CoV-2 gene targets as well as quickly investigating any unusual results with genetic sequencing. This is particularly in other countries where there is rampant spread of Covid-19. Fortunately, the prevalence of this novel SARS-CoV-2 mutation in Qatar is low, and it is unlikely that such viruses will escape detection locally because Covid-19 testing in Qatar is almost all based on detecting multiple viral targets,” he added.
The Sidra Medicine team comprised Dr. Mohammad Rubayet Hasan, Clinical Molecular Microbiologist; Dr. Sathyavathi Sundararaju, Research Specialist; Dr. Chidambaram Manickam, Staff Scientist Associate; Mr. Faheem Mirza, Senior Technologist; Mr. Hamad Al-Hail, Technologist; Dr. Stephan Lorenz, Director, Genomics Core; and Dr. Patrick Tang, Division Chief of Microbiology.
The finding of the research by this team has been published in the peer-reviewed Journal of Clinical Microbiology, published by the American Society of Microbiology: